Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022395 | 1.00 | NCF1 (0.34) | NCF1SLC6A2CXCR2HTR2AHTR2C | |
| SCHEMBL25040749 | 0.86 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL8320328 | 0.86 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL25041101 | 0.86 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL357188 | 0.85 | NCF1 (0.37) | NCF1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1902055 | 0.83 | NCF1 (0.36) | NCF1HTR2AHTR2C | |
| SCHEMBL19544957 | 0.82 | NCF1 (0.32) | NCF1SLC6A2CXCR2 | |
| SCHEMBL24801076 | 0.80 | NCF1 (0.37) | NCF1 | |
| SCHEMBL8318850 | 0.79 | — | — | |
| SCHEMBL20609823 | 0.79 | NCF1 (0.38) | NCF1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054766-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | MITO BIOPHARMA, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230246229-A1 | ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES | Octet Scientific, Inc. | 2023-08-03 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022090711-A1 | COMPOUNDS AS CD73 INHIBITORS | AdoRx Therapeutics Limited (GB) | 2022-05-05 | — | — | WO | disclosed |
| EP-3728220-B1 | PHARMACEUTICAL COMPOUNDS | REVIRAL LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| WO-2021050913-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| WO-2007046550-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007025284-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006090915-A1 | PYRIDYL ACETIC ACID COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006075160-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078189-B2 | Pharmaceutical compounds | HRH4, CHRM5, CHRM1 | NCF1 2903/4885SLC6A2 1482/4885CXCR2 1437/4885 |
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | NCF1 2481/4885SLC6A2 4813/4885CXCR2 3797/4885 |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | NCF1 2887/4885SLC6A2 3259/4885CXCR2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.